TQ Quiz | Optimizing Glaucoma Care: Managing the Comorbidities (Detroit 2025) by Events@optometricedu.com | Nov 10, 2025 | 2025 Detroit, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 90 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. Which risk factor for primary open angle glaucoma development shows significant overlap with risk factors for other ocular pathologies?* A - Age B - Sex C - Occupation D - Diet 2. In a personalized approach to open angle glaucoma management, how should the frequency of visual field testing be determined?* A - Based on the patient age only B - Based on individualized risk of disease progression C - Frequency of testing should be uniform for all patients D - Based solely on IOP 3. Other than glaucoma, what is another cause of arcuate retinal nerve fiber layer defect?* A - Cataract B - Retinal ischemia C - Macular neovascularization D - Retinal tear 4. To reduce patient fatigue when managing multiple ophthalmic conditions, what strategy optimizes testing frequency?* A - Stacking procedures on the same day when possible B - Increasing the frequency of clinical visits C - Duplicative testing D - Isolated specialist consultations 5. What is the characteristic finding of retinal ischemic perivascular lesions (RIPLs) on OCT?* A - Hyperreflective deposits in the outer retina B - Thickening of the retinal nerve fiber layer C - Focal atrophy of the inner nuclear layer and expansion of the outer nuclear layer D - Increased thickness of the retinal pigment epithelium 6. In primary open angle glaucoma, what is the primary mechanism leading to visual field damage?* A - Corneal thinning B - Progressive ganglion cell axonal loss C - Reduction in photoreceptor density D - Increased choroidal blood flow 7. Which systemic condition increases the risk for development of primary open angle glaucoma?* A - Asthma B - Diabetes mellitus C - Osteoarthritis D - Primary hypothyroidism 8. How do benzalkonium chloride (BAK)-preserved topical ophthalmic medications impact the ocular surface?* A - They improve tear film stability B - They can disrupt goblet cells and meibomian glands C - They increase eyelid laxity D - They decrease tear film evaporation 9. How can systemic antihypertensive medications affect ocular perfusion in glaucoma patients?* A - They increase intraocular pressure B - They do not impact ocular perfusion C - They may decrease ocular perfusion pressure D - They improve ocular perfusion pressure 10. What is a potential mechanism for IOP rise immediately after intravitreal injections?* A - Volume-related spike B - Increased aqueous production C - Reduced corneal endothelial function D - Acute angle closure crisis 11. How often should dilated retinal examination be performed in highly myopic glaucoma patients?* A - Based on risk, often annually or more frequently B - Every 3-5 years C - Only when symptomatic D - Dilated retinal examinations are not necessary 12. Which of the following OCT-based biomarkers indicates higher risk of age-related macular degeneration progression?* A - Hyperreflective foci B - Retinal pigment epithelium thickness C - Macular curvature index D - Vitreous opacity density 13. Which topical ophthalmic IOP-lowering medication contains a nitric-oxide donating moiety?* A - Latanoprostene bunod 0.024% (Vyzulta) B - Netarsudil 0.02% (Rhopressa) C - Dorzolamide 2% D - Preservative-free latanoprost 0.005% (Iyuzeh) 14. How does the volume differ between FDA approved intravitreal injections for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) from that of anti-VEGF agents?* A - The volume of GA treatments is larger B - The volume of GA treatment is smaller C - The volume of GA treatments is not relevant due to their route of administration D - The volume of GA treatments is 0.05mL 15. How may vitreomacular traction affect OCT imaging in glaucoma?* A - It may improve image quality B - It may decrease axial resolution C - It may lead to segmentation error D - It has no effect on OCT imaging 16. Which of the following features is central to differentiating non-glaucomatous optic neuropathy from glaucomatous optic neuropathy* A - Optic disc pallor B - Visual field defect C - Relative afferent pupillary defect D - Statistically normal intraocular pressure 17. All of the following features are relevant to determining a target IOP, EXCEPT:* A - Age B - Disease severity C - Peak, untreated IOP D - Presence of dry eye disease 18. Which clinical scenario is an indication for trabeculectomy?* A - Symptoms of dry eye disease with treatment on a single topical ophthalmic agent B - Early cataract with moderate stage primary open angle glaucoma C - Uncontrolled IOP despite maximally tolerated medical therapy D - It has no effect on OCT imaging 19. Which of the following agents is preservative-free?* A - Travatan Z (travoprost ophthalmic solution) 0.004% B - Iyuzeh (latanoprost ophthalmic solution) 0.005% C - Lumigan (bimatoprost ophthalmic solution) 0.01% D - Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% 20. What does the SPEED questionnaire stand for in the context of evaluating dry eye disease symptoms?* A - Standard Patient Evaluation of Eye Dryness B - Symptom Profile for Eye Evaluation and Diagnosis C - Special Patient Eye Examination and Detection D - Scale for Painful Eye Examination and Dryness Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodeDetroit 2025 - Optimizing Glaucoma Care: Managing the Comorbidities*After 90 days, pricing will increase to $30. Price: Retake Discount Price: Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
